In LPS-lesioned PD models, oral administration of vanillin reduced IL-1β, IL-6, and TNF-α expression through inhibition of the p38-MAPK signaling pathway, suppressing activation of NF-κB and inflammatory genes like iNOS that produce NO and COX-2. The gene discussed is NFKB1; the disease is Parkinson disease.